Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: Results from a randomized crossover trial

Transfusion

Volumn 56, Issue 1, 2016, Pages 261-270

  Rombout Sestrienkova, Eva ^a,g   Winkens, Bjorn ^b   Essers, Brigitte A B ^c   Nieman, Fred H M ^c   Noord, Paulus A H ^a   Janssen, Mirian C H ^d   Van Deursen, Cees Th B M ^e   Boonen, Annelies ^f   Reuser Kaasenbrood, Ellen P J M ^a   Heeremans, Judith ^a   Van Kraaij, Marian ^a   Masclee, Ad ^g   Koek, Ger H ^g  

^a CENTRAL LABORATORY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Department of Clinical Epidemiology and Medical Technology Assessment ^*  (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Zuyderland Medical Centre   (Netherlands)

^f Division of Rheumatology   (United States)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APHERESIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOCHROMATOSIS; HUMAN; MALE; MIDDLE AGED; PHLEBOTOMY; PROCEDURES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD COMPONENT REMOVAL; CROSS-OVER STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOCHROMATOSIS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PHLEBOTOMY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84954361636     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13328     Document Type: Article

References (37)

1. McDonnell SM, Preston BL, Jewell SA, et al., Survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619-24.
2. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3-22.
3. Bacon BR, Adams PC, Kowdley KV, et al., Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328-43.
4. Adams PC, Barton JC., How I treat hemochromatosis. Blood 2010; 116: 317-25.
5. Brissot P, Troadec MB, Bardou-Jacquet E, et al., Current approach to hemochromatosis. Blood Rev 2008; 22: 195-210.
6. Swinkels DW, Jorna AT, Raymakers RA., Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med 2007; 65: 452-5.
7. Brissot P, Ball S, Rofail D, et al., Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment. Transfusion 2011; 51: 1331-8.
8. McDonnel SM, Grindon AJ, Preston BL, et al., A survey of phlebotomy among persons with hemochromatosis. Transfusion 1999; 39: 651-6.
9. Rombout-Sestrienkova E, Nieman FH, Essers BA, et al., Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis: results from a randomized trial. Transfusion 2013; 52: 470-77.
10. Sundic T, Hervig T, Hannisdal S, et al., Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary hemochromatosis. Blood Transfus 2014; 12 Suppl 1: s.84-9.
11. Conte D, Brunelli L, Bozzani A, et al., Erythrocytapheresis in idiopathic haemochromatosis. Br Med J (Clin Res Ed) 1983; 286: 939.
12. Zoller WG, Kellner H, Spengel FA., Erythrocytapheresis. A method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients. Klin Wochenschr 1988; 66: 404-9.
13. Conte D, Mandelli C, Cesana M, et al., Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases. Int J Artif Organs 1989; 12: 59-62.
14. Kellner H, Zoller WG., Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol 1992; 30: 779-83.
15. Kohan A, Niborski R, Daruich J, et al., Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79: 40-5.
16. Muncunill J, Vaquer P, Galmés A, et al., In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher 2002; 17: 88-92.
17. Mariani R, Pelucchi S, Perseghin P, et al., Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90: 717-8.
18. Fernandez-Mosteirin N, Salvador-Osuna C, Garcia-Erce JA, et al., [Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations]. Med Clin (Barc) 2006; 127: 409-12.
19. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, et al., Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis-a pilot study. Transfus Apher Sci 2007; 36: 261-7.
20. Wijermans P, van Egmond L, Ypma P, et al., Isovolemic erythrocytapheresis technique as an alternative to conventional phlebotomy in patients with polycythemia rubra vera and hemochromatosis. Transfus Apher Sci 2009; 40: 137.
21. Aaronson NK, Muller M, Cohen PD, et al., Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 1055-68.
22. EuroQol Group. EuroQol-a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208.
23. Dolan P., Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108.
24. Brazier J, Roberts J, Deverill M., The estimation of a preference-based single index measure for health from the SF-36. J Health Econ 2002; 21: 271-92.
25. Cohen J., Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
26. Efron B, Tibshirani RJ., An introduction to the bootstrap. London: Chapman & Hall; 1993.
27. Hicken BL, Tucker DC, Barton JC., Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003; 98: 2072-7.
28. Carroll GJ, Breidahl WH, Bulsara MK, et al., Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum 2011; 63: 286-94.
29. Dymock IW, Hamilton EB, Laws JW, et al., Arthropathy of haemochromatosis. Ann Rheum Dis 1970; 29: 469-76.
30. Edwards CQ, Cartwright GE, Skolnick MH, et al., Homozygosity for hemochromatosis: clinical manifestations. Ann Intern Med 1980; 93: 519-25.
31. Huaux JP, Geubel A, Koch MC, et al., The arthritis of hemochromatosis. Clin Rheumatol 1986; 5: 317-24.
32. Schumacher HR, Straka PC, Krikker MA, et al., The arthropathy of hemochromatosis. Recent studies. Ann N Y Acad Sci 1988; 526: 224-33.
33. Faraawi R, Harth M, Kertesz A, et al., Arthritis in hemochromatosis. J Rheumatol 1993; 20: 448-52.
34. Sinigaglia L, Fargion S, Fracanzani AL, et al., Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997; 9: 1809-13.
35. Valenti L, Fracanzani AL, Rossi V, et al., The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. J Rheumatol 2008; 35: 153-8.
36. Richette P, Ottaviani S, Vicaut E, et al., Musculoskeletal complications of hereditary hemochromatosis: a case-control study. J Rheumatol 2010; 37: 2145-50.
37. Askari AD, Muir WA, Rosner IA, et al., Arthritis of hemochromatosis: clinical spectrum, relation of histocompatibility antigens and effectiveness of early phlebotomy. Am J Med 1983; 75: 957-65.